These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10980817)

  • 1. Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
    LeJemtel TH
    Curr Cardiol Rep; 1999 May; 1(1):31. PubMed ID: 10980817
    [No Abstract]   [Full Text] [Related]  

  • 2. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
    Cohn JN; Goldstein SO; Greenberg BH; Lorell BH; Bourge RC; Jaski BE; Gottlieb SO; McGrew F; DeMets DL; White BG
    N Engl J Med; 1998 Dec; 339(25):1810-6. PubMed ID: 9854116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vesnarinone for heart failure.
    Neely D
    N Engl J Med; 1994 Jan; 330(1):65. PubMed ID: 8259152
    [No Abstract]   [Full Text] [Related]  

  • 4. Vesnarinone for heart failure.
    Swedberg K; Wedel H
    N Engl J Med; 1994 Jan; 330(1):64; author reply 65. PubMed ID: 8259151
    [No Abstract]   [Full Text] [Related]  

  • 5. Vesnarinone for heart failure.
    Schwartz A; Grupp I; Grupp G
    N Engl J Med; 1994 Jan; 330(1):65; author reply 66. PubMed ID: 8259153
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
    Feldman AM; Bristow MR; Parmley WW; Carson PE; Pepine CJ; Gilbert EM; Strobeck JE; Hendrix GH; Powers ER; Bain RP
    N Engl J Med; 1993 Jul; 329(3):149-55. PubMed ID: 8515787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
    Kass DA; Van Anden E; Becker LC; Kasper EK; White WB; Feldman AM
    Am J Cardiol; 1996 Sep; 78(6):652-6. PubMed ID: 8831399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive inotropic agents: a double-edged sword for chronic heart failure.
    Asanoi H; Inoue H
    Intern Med; 1996 Jan; 35(1):63-4. PubMed ID: 8652942
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe heart failure: balancing length and quality of life.
    Harv Heart Lett; 1999 Jun; 9(10):1-2. PubMed ID: 10233785
    [No Abstract]   [Full Text] [Related]  

  • 10. Vesnarinone: a new inotropic agent for treating congestive heart failure.
    Cavusoglu E; Frishman WH; Klapholz M
    J Card Fail; 1995 Jun; 1(3):249-57. PubMed ID: 9420657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pitavastin in Japanese patients with chronic heart failure.
    D'Imperio H; Sanchis J; Núñez E; Núñez J
    Circ J; 2013; 77(8):2204. PubMed ID: 23759657
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of pitavastatin in Japanese patients with chronic heart failure. Reply.
    Takano H
    Circ J; 2013; 77(8):2205. PubMed ID: 23759658
    [No Abstract]   [Full Text] [Related]  

  • 13. Statin therapy in chronic heart failure: frog prince or bare frog?
    Kihara Y
    Circ J; 2013; 77(4):895-7. PubMed ID: 23502989
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of vesnarinone on cardiac function in patients with severe congestive heart failure.
    Scherrer-Crosbie M; Cocca-Spofford D; DiSalvo TG; Semigran MJ; Dec GW; Picard MH
    Am Heart J; 1998 Nov; 136(5):769-77. PubMed ID: 9812070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The search for the ideal positive inotropic agent.
    Packer M
    N Engl J Med; 1993 Jul; 329(3):201-2. PubMed ID: 8515793
    [No Abstract]   [Full Text] [Related]  

  • 16. Inotropic therapy for heart failure.
    Stevenson LW
    N Engl J Med; 1998 Dec; 339(25):1848-50. PubMed ID: 9854124
    [No Abstract]   [Full Text] [Related]  

  • 17. [Usefulness of OPC-8212, an inotropic agent, in patients with chronic congestive heart failure--a multiple dose evaluation on its effect and arrhythmogenesis].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Oct; 36(10):1125-31. PubMed ID: 3247528
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
    Soran O; Young JD; Holubkov R; Loftus S; Bourge R; Carson P; Jaski B; White BG; Feldman AM
    J Card Fail; 1999 Sep; 5(3):195-200; discussion 201-2. PubMed ID: 10496192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of vesnarinone.
    Feldman AM
    Drug Saf; 2004; 27 Suppl 1():1-9. PubMed ID: 15293848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.
    Matsumori A; Shioi T; Yamada T; Matsui S; Sasayama S
    Circulation; 1994 Mar; 89(3):955-8. PubMed ID: 8124835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.